Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. UBS has ...

IL-33 inhibitor itepekimab for chronic obstructive pulmonary disease (COPD), and vaccines against acne, extra-intestinal pathogenic Escherichia coli (EPEC), and respiratory syncytial virus (RSV).

which recently generated positive phase 2 data in the Tailwind study – along with Boehringer Ingelheim's cathepsin C Inhibitor BI-1291583 (phase 2), Sanofi's anti-IL-33 antibody itepekimab ...

UBS has decided Regeneron Pharmaceuticals needs a new wardrobe, trimming its price target from $633 to a more modest $560.

Regeneron Pharmaceuticals (NASDAQ:REGN) has reportedly declined to submit a higher bid for 23andMe (OTC:MEHCQ) after a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

Ivonescimab helped cut the risk of lung tumor progression in half in a multi-country Phase 3 trial. But it hasn’t yet clearly extended survival, which will be necessary to support an FDA submission.